Equity Overview
Price & Market Data
Price: $2.75
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $4,414,795
Volume: 0
Performance Metrics
1 Week: -21.43%
1 Month: -21.43%
3 Months: -32.93%
6 Months: -49.96%
1 Year: -47.62%
YTD: -14.06%
Company Details
Employees: 4
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Sigyn Therapeutics, Inc., a development-stage company, develops and sells medical devices to treat cancer and infectious disease disorders in the United States. Its lead product candidate is Sigyn therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community-acquired pneumonia, drug-resistant bacterial infections, and emerging pandemic threats. The company is also involved in the evaluation of Sigyn therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the performance of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.